ReviewImmune network2015
Immune-mediated Liver Injury in Hepatitis B Virus Infection.
Review in Immune network, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 63 citations in OpenAlex.
- Review
- Review
- Impact of hepatitis B virus infection in patients with plasmodium parasites in selected health facilities in Accra, Ghana.BMC infectious diseases · 2025Article
- Patients with chronic hepatitis B under nucleos(t)ide analog therapy with Omicron BA.5 infection: A retrospective study in South China.Liver research (Beijing, China) · 2025Article
- Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Sulforaphane effectively inhibits HBV by altering Treg/Th17 immune balance and the MIF-macrophages polarizing axis in vitro and in vivo.Virus research · 2024Article
- Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients.Frontiers in immunology · 2023Article
- Article
- Viral hepatitis: Past, present, and future.World journal of gastroenterology · 2022Review
- Mechanism of hydroxysafflor yellow A on acute liver injury based on transcriptomics.Frontiers in pharmacology · 2022Article
- Genomic characterization of rare molecular subclasses of hepatocellular carcinoma.Communications biology · 2021Article
- A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus.Scientific reports · 2021Article
- Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.International journal of molecular sciences · 2021Review
- Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly.PLoS pathogens · 2021Article
- Ginsenoside Rg1 alleviates acute liver injury through the induction of autophagy and suppressing NF-κB/NLRP3 inflammasome signaling pathway.International journal of medical sciences · 2021Article
- Loss of hepatocyte cell division leads to liver inflammation and fibrosis.PLoS genetics · 2020Article
- Protective effect of apigenin on d-galactosamine/LPS-induced hepatocellular injury by increment of Nrf-2 nucleus translocation.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- Hepatitis B virus infection and 1q21 amplification in multiple myeloma.Oncology letters · 2019Article
- Total flavonoids from Tetrastigma hemsleyanum ameliorates inflammatory stress in concanavalin A-induced autoimmune hepatitis mice by regulating Treg/Th17 immune homeostasis.Inflammopharmacology · 2019Article
- Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) is responsible for approximately 350 million chronic infections worldwide and is a leading cause of broad-spectrum liver diseases such as hepatitis, cirrhosis and liver cancer. Although it has been well established that adaptive immunity plays a critical role in viral clearance, the pathogenetic mechanisms that cause liver damage during acute and chronic HBV infection remain largely known. This review describes our current knowledge of the immune-mediated pathogenesis of HBV infection and the role of immune cells in the liver injury during hepatitis B.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.